Sodium Phosphates
Brand Names: Sodium Phosphates Generic
Methodology & AI Transparency ⓘ
Sodium Phosphates Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: INDICATIONS & USAGE Sodium phosphates injection, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake.
- 2 Real-world patient consensus: Zero-PHI community consensus: 89% favorable across 16 logged regimens (Sodium Phosphates Generic).
- 3 Typical cash cost range: Public pharmacy ledger: $98.82 low cash benchmark vs. $242.11 chain retail average ($2.2300/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Sodium Phosphates): nausea (7.9%), headache (7.9%), dizziness (5.5%).
Ask our AI Specialists anything about Sodium Phosphates
Sodium Phosphates Mechanism, CYP450 Pathways & DailyMed Monograph
INDICATIONS & USAGE Sodium phosphates injection, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (Na + 4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions.
CLINICAL PHARMACOLOGY Phosphorus in the form of organic and inorganic phosphate has a variety of important biochemical functions in the body and is involved in many significant metabolic and enzyme reactions in almost all organs and tissues. It exerts a modifying influence on the steady state of calcium levels, a buffering effect on acid-base equilibrium and a primary role in the renal excretion of hydrogen ion. Phosphorus is present in plasma and other extracellular fluid, in cell membranes and intracellular fluid, as well as in collagen and bone tissues.
Pharmacokinetic profiling of Sodium Phosphates demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 9–19 hour t½ intervals for Sodium Phosphates with Complete (~100%) parenteral systemic delivery for Sodium Phosphates (276 mg/mL / 268 mg/mL Injection, Solution) systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar sodium phosphates conjugates, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after sodium phosphates administration.
Titration schedules for Sodium Phosphates (276 mg/mL / 268 mg/mL Injection, Solution → Maintenance adjustment for Sodium Phosphates based on hepatic/renal clearance) require excluding contraindications sodium phosphate is contraindicated in diseases where high phosphorus or low calcium levels may be encountered, and in patients with hypernatremia.; confirmed ige-mediated allergy or cutaneous reaction to sodium phosphates (sodium phosphates) components; real-world patient logs highlight nausea (7.9% of reports), headache (7.9% of reports), fatigue (5.6% of reports) alongside a 89.00% Worth-It consensus.
Separate Sodium Phosphates ingestion from mineral supplements or antacids to preserve gastrointestinal bioavailability.
Reconcile eGFR-adjusted medications before escalating Sodium Phosphates in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Sodium phosphate is contraindicated in diseases where high phosphorus or low calcium levels may be encountered, and in patients with hypernatremia.
- Confirmed IgE-mediated allergy or cutaneous reaction to Sodium Phosphates (Sodium Phosphates) components
Logged Side-Effect Incidence (16 Reports)
Sodium Phosphates Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sodium Phosphates)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
| Check Your Medicine Cabinet: FDA Enforcement Recall D-0039-2027 (Class II): Hydrocortisone Sodium Succinate for Injec Reason for recall: Failed Impurities/Degradation Specifications. openFDA Drug Enforcement & Recall Registry • 2026-10-21 • FDA Drug Recall (Class II) | Multi-cohort | 96/100 | PMID FDARECALL-D-0039-2027 ↗ |
| New Insights on Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in: What a 4,300-Participant Study Found Despite similar glycemic efficacy in a relatively short term, SGLT2 inhibitors are more effective in the longer term than SUs as add-on to metformin. Clinical drug investigation • 2019-06-15 • Meta-Analysis | N = 4,300 | 94/100 | PMID 31041606 ↗ |
| New Insights on Safety and real-world benefits of Tenapanor for Long-term Serum Phosphate Control: What a 423-Participant Study Found Tenapanor reduced serum phosphate concentrations and maintained control of serum phosphate in participants receiving maintenance dialysis, with an acceptable safety and tolerability profile. Kidney360 • 2021-10-28 • Phase III Randomized Trial | N = 423 | 93/100 | PMID 35372979 ↗ |
| New Insights on Modified-release nicotinamide for the treatment of hyperphosphataemia in: What a 358-Participant Study Found NAMR combined with phosphate binders significantly reduced serum phosphate over the first 24 weeks of treatment, but the treatment effect was not maintained up to week 52. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2023-03-31 • Phase III Randomized Trial | N = 358 | 93/100 | PMID 35751625 ↗ |
Sodium Phosphates Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.2300/unit (~$66.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $242.11 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $98.82 / mo | View logs ↓ |
Sodium Phosphates Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Sodium Phosphates RxNorm Concept ID | 1872384 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.2300 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $242.11 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $98.82 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Sodium Phosphates Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Sodium Phosphates: FDA labeling (2026-03-10, NDC 65145-200), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Sodium Phosphates community threads and patient logs by age, biological sex, dosage, and treatment duration.